CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case Series

To explore whether hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and neurologic symptoms have evidence of CNS infection, inflammation, and injury using CSF biomarker measurements. We assessed CSF SARS-CoV-2 RNA along with CSF biomarkers of intrathecal inflam...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurology 2021-01, Vol.96 (2), p.e294-e300
Hauptverfasser: Edén, Arvid, Kanberg, Nelly, Gostner, Johanna, Fuchs, Dietmar, Hagberg, Lars, Andersson, Lars-Magnus, Lindh, Magnus, Price, Richard W., Zetterberg, Henrik, Gisslén, Magnus
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e300
container_issue 2
container_start_page e294
container_title Neurology
container_volume 96
creator Edén, Arvid
Kanberg, Nelly
Gostner, Johanna
Fuchs, Dietmar
Hagberg, Lars
Andersson, Lars-Magnus
Lindh, Magnus
Price, Richard W.
Zetterberg, Henrik
Gisslén, Magnus
description To explore whether hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and neurologic symptoms have evidence of CNS infection, inflammation, and injury using CSF biomarker measurements. We assessed CSF SARS-CoV-2 RNA along with CSF biomarkers of intrathecal inflammation (CSF white blood cell count, neopterin, β -microglobulin, and immunoglobulin G index), blood-brain barrier integrity (albumin ratio), and axonal injury (CSF neurofilament light chain protein [NfL]) in 6 patients with moderate to severe coronavirus disease 2019 (COVID-19) and neurologic symptoms who had undergone a diagnostic lumbar puncture. Neurologic symptoms and signs included features of encephalopathies (4 of 6), suspected meningitis (1 of 6), and dysgeusia (1 of 6). SARS-CoV-2 infection was confirmed by real-time PCR analysis of nasopharyngeal swabs. SARS-CoV-2 RNA was detected in the plasma of 2 patients (cycle threshold [Ct] value 35.0-37.0) and in CSF at low levels (Ct 37.2, 38.0, 39.0) in 3 patients in 1 but not in a second real-time PCR assay. CSF neopterin (median 43.0 nmol/L) and β -microglobulin (median 3.1 mg/L) were increased in all. Median immunoglobulin G index (0.39), albumin ratio (5.35), and CSF white blood cell count (
doi_str_mv 10.1212/WNL.0000000000010977
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2448402008</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2448402008</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3014-e35da28d2ef0e01fe35ce8b690638c9818ce2f9a58bffdf0c4f901e83895c82b3</originalsourceid><addsrcrecordid>eNpdkElPwzAQhS0EgrL8A4R85JIyHiepww3CKlUUqWy3yHXGNJA0xU6E-PeYXWIuoxm9eaP3MbYrYChQ4MH91XgIfyUgG41W2EAkmEapxIdVNgBAFUk1Uhts0_unIEpwlK2zDSkB4hRwwCb59IwfV22j3TM5z6sFv9ZdRYvO8_uqm_N8cnd5EomM60XJr6h3bd0-VoZP35pl1zb-kB_xXHviU3IV-W22ZnXtaee7b7Hbs9Ob_CIaT84v86NxZCSIOCKZlBpViWSBQNgwG1KzNINUKpMpoQyhzXSiZtaWFkxsMxCkpMoSo3Amt9j-l-_StS89-a5oKm-orvWC2t4XGMcqBgRQQRp_SY1rvXdki6WrQt63QkDxgbIIKIv_KMPZ3veHftZQ-Xv0w-7P97Wtu8Duue5fyRVz0nU3__RLRYiKgAKEQIjCBmP5DsjLfCA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2448402008</pqid></control><display><type>article</type><title>CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case Series</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>Edén, Arvid ; Kanberg, Nelly ; Gostner, Johanna ; Fuchs, Dietmar ; Hagberg, Lars ; Andersson, Lars-Magnus ; Lindh, Magnus ; Price, Richard W. ; Zetterberg, Henrik ; Gisslén, Magnus</creator><creatorcontrib>Edén, Arvid ; Kanberg, Nelly ; Gostner, Johanna ; Fuchs, Dietmar ; Hagberg, Lars ; Andersson, Lars-Magnus ; Lindh, Magnus ; Price, Richard W. ; Zetterberg, Henrik ; Gisslén, Magnus</creatorcontrib><description>To explore whether hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and neurologic symptoms have evidence of CNS infection, inflammation, and injury using CSF biomarker measurements. We assessed CSF SARS-CoV-2 RNA along with CSF biomarkers of intrathecal inflammation (CSF white blood cell count, neopterin, β -microglobulin, and immunoglobulin G index), blood-brain barrier integrity (albumin ratio), and axonal injury (CSF neurofilament light chain protein [NfL]) in 6 patients with moderate to severe coronavirus disease 2019 (COVID-19) and neurologic symptoms who had undergone a diagnostic lumbar puncture. Neurologic symptoms and signs included features of encephalopathies (4 of 6), suspected meningitis (1 of 6), and dysgeusia (1 of 6). SARS-CoV-2 infection was confirmed by real-time PCR analysis of nasopharyngeal swabs. SARS-CoV-2 RNA was detected in the plasma of 2 patients (cycle threshold [Ct] value 35.0-37.0) and in CSF at low levels (Ct 37.2, 38.0, 39.0) in 3 patients in 1 but not in a second real-time PCR assay. CSF neopterin (median 43.0 nmol/L) and β -microglobulin (median 3.1 mg/L) were increased in all. Median immunoglobulin G index (0.39), albumin ratio (5.35), and CSF white blood cell count (&lt;3 cells/µL) were normal in all, while CSF NfL was elevated in 2 patients. Our results in patients with COVID-19 and neurologic symptoms suggest an unusual pattern of marked CSF inflammation in which soluble markers were increased but white cell response and other immunologic features typical of CNS viral infections were absent. While our initial hypothesis centered on CNS SARS-CoV-2 invasion, we could not convincingly detect SARS-CoV-2 as the underlying driver of CNS inflammation. These features distinguish COVID-19 CSF from other viral CNS infections and raise fundamental questions about the CNS pathobiology of SARS-CoV-2 infection.</description><identifier>ISSN: 0028-3878</identifier><identifier>EISSN: 1526-632X</identifier><identifier>DOI: 10.1212/WNL.0000000000010977</identifier><identifier>PMID: 33004602</identifier><language>eng</language><publisher>United States: American Academy of Neurology</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biomarkers - cerebrospinal fluid ; Blood-Brain Barrier - diagnostic imaging ; Blood-Brain Barrier - metabolism ; COVID-19 - cerebrospinal fluid ; COVID-19 - complications ; COVID-19 - diagnostic imaging ; Female ; Humans ; Male ; Middle Aged ; Nervous System Diseases - cerebrospinal fluid ; Nervous System Diseases - diagnostic imaging ; Nervous System Diseases - etiology ; SARS-CoV-2 - isolation &amp; purification</subject><ispartof>Neurology, 2021-01, Vol.96 (2), p.e294-e300</ispartof><rights>American Academy of Neurology</rights><rights>2020 American Academy of Neurology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3014-e35da28d2ef0e01fe35ce8b690638c9818ce2f9a58bffdf0c4f901e83895c82b3</cites><orcidid>0000-0003-1532-5177</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33004602$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Edén, Arvid</creatorcontrib><creatorcontrib>Kanberg, Nelly</creatorcontrib><creatorcontrib>Gostner, Johanna</creatorcontrib><creatorcontrib>Fuchs, Dietmar</creatorcontrib><creatorcontrib>Hagberg, Lars</creatorcontrib><creatorcontrib>Andersson, Lars-Magnus</creatorcontrib><creatorcontrib>Lindh, Magnus</creatorcontrib><creatorcontrib>Price, Richard W.</creatorcontrib><creatorcontrib>Zetterberg, Henrik</creatorcontrib><creatorcontrib>Gisslén, Magnus</creatorcontrib><title>CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case Series</title><title>Neurology</title><addtitle>Neurology</addtitle><description>To explore whether hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and neurologic symptoms have evidence of CNS infection, inflammation, and injury using CSF biomarker measurements. We assessed CSF SARS-CoV-2 RNA along with CSF biomarkers of intrathecal inflammation (CSF white blood cell count, neopterin, β -microglobulin, and immunoglobulin G index), blood-brain barrier integrity (albumin ratio), and axonal injury (CSF neurofilament light chain protein [NfL]) in 6 patients with moderate to severe coronavirus disease 2019 (COVID-19) and neurologic symptoms who had undergone a diagnostic lumbar puncture. Neurologic symptoms and signs included features of encephalopathies (4 of 6), suspected meningitis (1 of 6), and dysgeusia (1 of 6). SARS-CoV-2 infection was confirmed by real-time PCR analysis of nasopharyngeal swabs. SARS-CoV-2 RNA was detected in the plasma of 2 patients (cycle threshold [Ct] value 35.0-37.0) and in CSF at low levels (Ct 37.2, 38.0, 39.0) in 3 patients in 1 but not in a second real-time PCR assay. CSF neopterin (median 43.0 nmol/L) and β -microglobulin (median 3.1 mg/L) were increased in all. Median immunoglobulin G index (0.39), albumin ratio (5.35), and CSF white blood cell count (&lt;3 cells/µL) were normal in all, while CSF NfL was elevated in 2 patients. Our results in patients with COVID-19 and neurologic symptoms suggest an unusual pattern of marked CSF inflammation in which soluble markers were increased but white cell response and other immunologic features typical of CNS viral infections were absent. While our initial hypothesis centered on CNS SARS-CoV-2 invasion, we could not convincingly detect SARS-CoV-2 as the underlying driver of CNS inflammation. These features distinguish COVID-19 CSF from other viral CNS infections and raise fundamental questions about the CNS pathobiology of SARS-CoV-2 infection.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers - cerebrospinal fluid</subject><subject>Blood-Brain Barrier - diagnostic imaging</subject><subject>Blood-Brain Barrier - metabolism</subject><subject>COVID-19 - cerebrospinal fluid</subject><subject>COVID-19 - complications</subject><subject>COVID-19 - diagnostic imaging</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nervous System Diseases - cerebrospinal fluid</subject><subject>Nervous System Diseases - diagnostic imaging</subject><subject>Nervous System Diseases - etiology</subject><subject>SARS-CoV-2 - isolation &amp; purification</subject><issn>0028-3878</issn><issn>1526-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkElPwzAQhS0EgrL8A4R85JIyHiepww3CKlUUqWy3yHXGNJA0xU6E-PeYXWIuoxm9eaP3MbYrYChQ4MH91XgIfyUgG41W2EAkmEapxIdVNgBAFUk1Uhts0_unIEpwlK2zDSkB4hRwwCb59IwfV22j3TM5z6sFv9ZdRYvO8_uqm_N8cnd5EomM60XJr6h3bd0-VoZP35pl1zb-kB_xXHviU3IV-W22ZnXtaee7b7Hbs9Ob_CIaT84v86NxZCSIOCKZlBpViWSBQNgwG1KzNINUKpMpoQyhzXSiZtaWFkxsMxCkpMoSo3Amt9j-l-_StS89-a5oKm-orvWC2t4XGMcqBgRQQRp_SY1rvXdki6WrQt63QkDxgbIIKIv_KMPZ3veHftZQ-Xv0w-7P97Wtu8Duue5fyRVz0nU3__RLRYiKgAKEQIjCBmP5DsjLfCA</recordid><startdate>20210112</startdate><enddate>20210112</enddate><creator>Edén, Arvid</creator><creator>Kanberg, Nelly</creator><creator>Gostner, Johanna</creator><creator>Fuchs, Dietmar</creator><creator>Hagberg, Lars</creator><creator>Andersson, Lars-Magnus</creator><creator>Lindh, Magnus</creator><creator>Price, Richard W.</creator><creator>Zetterberg, Henrik</creator><creator>Gisslén, Magnus</creator><general>American Academy of Neurology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1532-5177</orcidid></search><sort><creationdate>20210112</creationdate><title>CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case Series</title><author>Edén, Arvid ; Kanberg, Nelly ; Gostner, Johanna ; Fuchs, Dietmar ; Hagberg, Lars ; Andersson, Lars-Magnus ; Lindh, Magnus ; Price, Richard W. ; Zetterberg, Henrik ; Gisslén, Magnus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3014-e35da28d2ef0e01fe35ce8b690638c9818ce2f9a58bffdf0c4f901e83895c82b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers - cerebrospinal fluid</topic><topic>Blood-Brain Barrier - diagnostic imaging</topic><topic>Blood-Brain Barrier - metabolism</topic><topic>COVID-19 - cerebrospinal fluid</topic><topic>COVID-19 - complications</topic><topic>COVID-19 - diagnostic imaging</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nervous System Diseases - cerebrospinal fluid</topic><topic>Nervous System Diseases - diagnostic imaging</topic><topic>Nervous System Diseases - etiology</topic><topic>SARS-CoV-2 - isolation &amp; purification</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Edén, Arvid</creatorcontrib><creatorcontrib>Kanberg, Nelly</creatorcontrib><creatorcontrib>Gostner, Johanna</creatorcontrib><creatorcontrib>Fuchs, Dietmar</creatorcontrib><creatorcontrib>Hagberg, Lars</creatorcontrib><creatorcontrib>Andersson, Lars-Magnus</creatorcontrib><creatorcontrib>Lindh, Magnus</creatorcontrib><creatorcontrib>Price, Richard W.</creatorcontrib><creatorcontrib>Zetterberg, Henrik</creatorcontrib><creatorcontrib>Gisslén, Magnus</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Edén, Arvid</au><au>Kanberg, Nelly</au><au>Gostner, Johanna</au><au>Fuchs, Dietmar</au><au>Hagberg, Lars</au><au>Andersson, Lars-Magnus</au><au>Lindh, Magnus</au><au>Price, Richard W.</au><au>Zetterberg, Henrik</au><au>Gisslén, Magnus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case Series</atitle><jtitle>Neurology</jtitle><addtitle>Neurology</addtitle><date>2021-01-12</date><risdate>2021</risdate><volume>96</volume><issue>2</issue><spage>e294</spage><epage>e300</epage><pages>e294-e300</pages><issn>0028-3878</issn><eissn>1526-632X</eissn><abstract>To explore whether hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and neurologic symptoms have evidence of CNS infection, inflammation, and injury using CSF biomarker measurements. We assessed CSF SARS-CoV-2 RNA along with CSF biomarkers of intrathecal inflammation (CSF white blood cell count, neopterin, β -microglobulin, and immunoglobulin G index), blood-brain barrier integrity (albumin ratio), and axonal injury (CSF neurofilament light chain protein [NfL]) in 6 patients with moderate to severe coronavirus disease 2019 (COVID-19) and neurologic symptoms who had undergone a diagnostic lumbar puncture. Neurologic symptoms and signs included features of encephalopathies (4 of 6), suspected meningitis (1 of 6), and dysgeusia (1 of 6). SARS-CoV-2 infection was confirmed by real-time PCR analysis of nasopharyngeal swabs. SARS-CoV-2 RNA was detected in the plasma of 2 patients (cycle threshold [Ct] value 35.0-37.0) and in CSF at low levels (Ct 37.2, 38.0, 39.0) in 3 patients in 1 but not in a second real-time PCR assay. CSF neopterin (median 43.0 nmol/L) and β -microglobulin (median 3.1 mg/L) were increased in all. Median immunoglobulin G index (0.39), albumin ratio (5.35), and CSF white blood cell count (&lt;3 cells/µL) were normal in all, while CSF NfL was elevated in 2 patients. Our results in patients with COVID-19 and neurologic symptoms suggest an unusual pattern of marked CSF inflammation in which soluble markers were increased but white cell response and other immunologic features typical of CNS viral infections were absent. While our initial hypothesis centered on CNS SARS-CoV-2 invasion, we could not convincingly detect SARS-CoV-2 as the underlying driver of CNS inflammation. These features distinguish COVID-19 CSF from other viral CNS infections and raise fundamental questions about the CNS pathobiology of SARS-CoV-2 infection.</abstract><cop>United States</cop><pub>American Academy of Neurology</pub><pmid>33004602</pmid><doi>10.1212/WNL.0000000000010977</doi><orcidid>https://orcid.org/0000-0003-1532-5177</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0028-3878
ispartof Neurology, 2021-01, Vol.96 (2), p.e294-e300
issn 0028-3878
1526-632X
language eng
recordid cdi_proquest_miscellaneous_2448402008
source MEDLINE; Alma/SFX Local Collection; Journals@Ovid Complete
subjects Adult
Aged
Aged, 80 and over
Biomarkers - cerebrospinal fluid
Blood-Brain Barrier - diagnostic imaging
Blood-Brain Barrier - metabolism
COVID-19 - cerebrospinal fluid
COVID-19 - complications
COVID-19 - diagnostic imaging
Female
Humans
Male
Middle Aged
Nervous System Diseases - cerebrospinal fluid
Nervous System Diseases - diagnostic imaging
Nervous System Diseases - etiology
SARS-CoV-2 - isolation & purification
title CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case Series
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T04%3A19%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CSF%20Biomarkers%20in%20Patients%20With%20COVID-19%20and%20Neurologic%20Symptoms:%20A%20Case%20Series&rft.jtitle=Neurology&rft.au=Ed%C3%A9n,%20Arvid&rft.date=2021-01-12&rft.volume=96&rft.issue=2&rft.spage=e294&rft.epage=e300&rft.pages=e294-e300&rft.issn=0028-3878&rft.eissn=1526-632X&rft_id=info:doi/10.1212/WNL.0000000000010977&rft_dat=%3Cproquest_cross%3E2448402008%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2448402008&rft_id=info:pmid/33004602&rfr_iscdi=true